Stock Track | Tempus AI Soars 5.12% Intraday on Promising KMT2C Biomarker Research

Stock Track04-14

Tempus AI's stock surged 5.12% during Tuesday's intraday trading session following the release of significant new research findings.

The company presented real-world evidence linking KMT2C mutations to improved survival outcomes for patients on platinum-based chemotherapy for solid tumors. The findings, which were validated in an external cancer dataset, showed the strongest signal in colorectal cancer, positioning KMT2C as a potential biomarker to guide chemotherapy selection in gastrointestinal cancers.

Tempus indicated that follow-on laboratory work is underway to clarify the biological drivers, supporting potential clinical adoption and partner interest in biomarker-led treatment strategies. The research is scheduled for an oral presentation at the AACR Annual Meeting 2026 in San Diego.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1127772921?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 21:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1127772921","market":"hk","top_or_hot":-1,"title":"Stock Track | Tempus AI Soars 5.12% Intraday on Promising KMT2C Biomarker Research","media":"Stock Track","content":"<p>Tempus AI's stock surged 5.12% during Tuesday's intraday trading session following the release of significant new research findings.</p><p>The company presented real-world evidence linking KMT2C mutations to improved survival outcomes for patients on platinum-based chemotherapy for solid tumors. The findings, which were validated in an external cancer dataset, showed the strongest signal in colorectal cancer, positioning KMT2C as a potential biomarker to guide chemotherapy selection in gastrointestinal cancers.</p><p>Tempus indicated that follow-on laboratory work is underway to clarify the biological drivers, supporting potential clinical adoption and partner interest in biomarker-led treatment strategies. The research is scheduled for an oral presentation at the AACR Annual Meeting 2026 in San Diego.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Tempus AI Soars 5.12% Intraday on Promising KMT2C Biomarker Research</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Tempus AI Soars 5.12% Intraday on Promising KMT2C Biomarker Research\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2026-04-14 21:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tempus AI's stock surged 5.12% during Tuesday's intraday trading session following the release of significant new research findings.</p><p>The company presented real-world evidence linking KMT2C mutations to improved survival outcomes for patients on platinum-based chemotherapy for solid tumors. The findings, which were validated in an external cancer dataset, showed the strongest signal in colorectal cancer, positioning KMT2C as a potential biomarker to guide chemotherapy selection in gastrointestinal cancers.</p><p>Tempus indicated that follow-on laboratory work is underway to clarify the biological drivers, supporting potential clinical adoption and partner interest in biomarker-led treatment strategies. The research is scheduled for an oral presentation at the AACR Annual Meeting 2026 in San Diego.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1127772921","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1127772921","pubTimestamp":1776174125,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Tempus AI's stock surged 5.12% during Tuesday's intraday trading session following the release of significant new research findings.The company presented real-world evidence linking KMT2C mutations...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"个股追踪|腾邦AI盘中大涨5.12%KMT2C生物标志物研究前景看好","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"Tempus AI's stock surged 5.12% during Tuesday's intraday trading session following the release of significant new research findings.The company presented real-world evidence linking KMT2C mutations to improved survival outcomes for patients on platinum-based chemotherapy for solid tumors. The findings, which were validated in an external cancer dataset, showed the strongest signal in colorectal cancer, positioning KMT2C as a potential biomarker to guide chemotherapy selection in gastrointestinal cancers.Tempus indicated that follow-on laboratory work is underway to clarify the biological drivers, supporting potential clinical adoption and partner interest in biomarker-led treatment strategies. The research is scheduled for an oral presentation at the AACR Annual Meeting 2026 in San Diego.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1127772921","isCrawlerRequest":true}